Harmony Biosciences Holdings (HRMY) Debt to Equity (2019 - 2026)

Harmony Biosciences Holdings has disclosed Debt to Equity across 8 years of filings, most recently posting $0.17 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.17, down 28.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.17 (down 28.45% YoY), and the FY2025 annual result was $0.19, down 30.85% from the prior year.
• Debt to Equity came in at $0.17 for Q1 2026 at Harmony Biosciences Holdings, down from $0.19 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.89 in Q1 2022 to a low of $0.17 in Q1 2026.
• The 5-year median for Debt to Equity is $0.37 (2024), against an average of $0.39.
• Across the five-year window, Debt to Equity sank 55.87% in 2022 and fell 12.3% in 2024, its largest moves.
• Harmony Biosciences Holdings' Debt to Equity stood at $0.48 in 2022, then fell by 12.87% to $0.41 in 2023, then tumbled by 34.39% to $0.27 in 2024, then tumbled by 30.85% to $0.19 in 2025, then slipped by 7.24% to $0.17 in 2026.
• The last three Debt to Equity figures came in at $0.17 (Q1 2026), $0.19 (Q4 2025), and $0.2 (Q3 2025), per Business Quant data.